[ad_1]
CUPERTINO, CA / ACCESSWIRE / October 13, 2022 / Reviva Prescribed drugs Holdings, Inc. (NASDAQ:RVPH), (“Reviva” or the “Firm”), a clinical-stage pharmaceutical firm growing therapies that search to deal with unmet medical wants within the areas of central nervous system (CNS), respiratory and metabolic ailments, as we speak introduced that an interview with Founder, President and CEO Dr. Laxminarayan Bhat will air on The RedChip Cash Report® on Bloomberg TV, this Saturday, October 15, at 7 p.m. Japanese Time (ET). Bloomberg TV is offered in an estimated 73 million houses throughout the U.S.
Interview highlights:
Within the unique RedChip Cash Report interview, Reviva’s Founder & CEO Dr. Laxminarayan Bhat discusses the Firm’s robust insider assist, the anticipated learn outs from the Section 3 trials in mid-2023, and far more.
Entry this interview in its entirety at https://www.rvphinfo.com/interview_access
About The RedChip Cash Report®
The RedChip Cash Report® is produced by RedChip Firms Inc., a world Investor Relations and media agency with 30 years’ expertise targeted on Discovering Tomorrow’s Blue Chips In the present day™. “The RedChip Cash Report®” delivers insightful commentary on small-cap investing, interviews with Wall Avenue analysts, monetary ebook evaluations, in addition to featured interviews with executives of public corporations.
About Reviva Prescribed drugs Holdings, Inc.
Reviva is a clinical-stage biopharmaceutical firm that discovers, develops, and seeks to commercialize next-generation therapeutics for ailments representing unmet medical wants and burdens to society, sufferers, and their households. Reviva’s present pipeline focuses on the central nervous system, respiratory and metabolic ailments. Reviva’s pipeline presently consists of two drug candidates, RP5063 (brilaroxazine) and RP1208. Each are new chemical entities found in-house. Reviva has been granted composition of matter patents for each RP5063 and RP1208 in the USA (U.S.), Europe, and several other different nations.
About RedChip Firms
RedChip Firms, an Inc. 5000 firm, is a world investor relations, media, and analysis agency targeted on microcap and small-cap corporations. For 30 years, RedChip has delivered concrete, measurable outcomes for its shoppers. Our e-newsletter, the RedChip Cash Report is delivered on-line weekly to 60,000 buyers. RedChip has developed probably the most complete service platform within the business for microcap and small-cap corporations. These companies embody the next: a worldwide distribution community for its inventory analysis; retail and institutional roadshows in main U.S. cities; outbound advertising to inventory brokers, RIAs, establishments, and household workplaces; a digital media investor relations platform that has generated tens of millions of distinctive investor views; investor webinars and group calls; a tv present, “The RedChip Cash Report,” which airs weekly on Bloomberg US; TV commercials in native and nationwide markets; company and product movies; web site design; and conventional investor relation companies, which embody press launch writing, growth of investor displays, quarterly convention name script writing, strategic consulting, capital elevating, and extra.
To be taught extra about RedChip’s services and products, please go to:
https://www.redchip.com/company/investor_relations
“Discovering Tomorrow’s Blue Chips In the present day”™
Ahead Wanting Statements
This press launch accommodates sure forward-looking statements throughout the which means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 and the Non-public Securities Litigation Reform Act, as amended, together with these referring to the Firm’s product growth, scientific and regulatory timelines and bills, market alternative, capability to lift ample funding, aggressive place, potential or assumed future outcomes of operations, enterprise methods, potential progress alternatives and different statements which might be predictive in nature. These forward-looking statements are based mostly on present expectations, estimates, forecasts and projections in regards to the business and markets through which we function and administration’s present beliefs and assumptions. These statements could also be recognized by means of forward-looking expressions, together with, however not restricted to, “count on,” “anticipate,” “intend,” “plan,” “consider,” “estimate,” “potential, “predict,” “undertaking,” “ought to,” “would” and comparable expressions and the negatives of these phrases. These statements relate to future occasions or our monetary efficiency and contain recognized and unknown dangers, uncertainties, and different elements which can trigger precise outcomes, efficiency or achievements to be materially totally different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements. Such elements embody these set forth within the Firm’s filings with the Securities and Alternate Fee. Potential buyers are cautioned to not place undue reliance on such forward-looking statements, which communicate solely as of the date of this press launch. The Firm undertakes no obligation to publicly replace any forward-looking assertion, whether or not on account of new data, future occasions or in any other case.
Company Contact:
Reviva Prescribed drugs Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
Dave Gentry
RedChip Firms Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
[email protected]
SOURCE: RedChip
View supply model on accesswire.com:
https://www.accesswire.com/720278/Reviva-Prescribed drugs-Holdings-Inc-Interview-to-Air-on-Bloomberg-US-on-the-RedChip-Cash-ReportR
[ad_2]
Source link
